8-K filed April 30, 2026, 7:59 PM ET ticker NTLA CIK 0001652130

other material confidence high sentiment neutral materiality 0.70

Intellia raises ~$194.6M in public offering of 16.7M shares at $10.75; preliminary cash $517.2M as of March 31

Intellia Therapeutics, Inc.

Offered 16,744,187 shares at $10.75/share; underwriters exercised full option for 2,511,628 additional shares; net proceeds ~$194.6M.
Proceeds will advance clinical development and commercial launch prep for lonvoguran ziclumeran (HAE), pipeline R&D, and potential acquisitions.
Preliminary unaudited cash, cash equivalents and marketable securities as of March 31, 2026: ~$517.2M; raised $33.6M from ATM program in Q1.
Company expects combined cash to fund expenses into 2028, excluding potential HAE product revenue, milestone payments, or strategic capital.
Potential FDA approval of lonvoguran ziclumeran for hereditary angioedema anticipated in first half of 2027.

item 1.01 item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-197489
form_type: 8-K
ticker: NTLA
cik: 0001652130
company_name: Intellia Therapeutics, Inc.
filed_at: 2026-04-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.669819+00:00
generated_at: 2026-05-15T00:58:30.606208+00:00
sec_items: ["1.01", "2.02", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-197489
json_url: https://secwatch.observer/filing/0001193125-26-197489.json
markdown_url: https://secwatch.observer/filing/0001193125-26-197489.md
text_url: https://secwatch.observer/filing/0001193125-26-197489.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/0001193125-26-197489-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526197489/d308328d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

3c54501152111bcfa97dec58c4726bcbc91768b2

Intellia Therapeutics, Inc. reported preliminary financial results for quarter ended March 31, 2026.

On April 27, 2026, the Company disclosed in a preliminary prospectus supplement related to the Offering that its preliminary unaudited cash, cash equivalents and marketable securities as of March 31, 2026 were approximately $517.2 million.

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

0606be06ed8108fac6462f321f55014da1721fb6

Intellia Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. valued at approximately $194.6 million (effective 2026-04-28).

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

Comparable filing

On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).

Filing page SEC filing

GIPR

Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit

GENERATION INCOME PROPERTIES, INC. June 1, 2026, 5:27 PM ET other_material Items 1.01, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

Comparable filing

In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent

Filing page SEC filing

LOKV

Live Oak enters Forward Purchase Agreement to back Teamshares merger, up to 4M shares at ~$10.54

Live Oak Acquisition Corp. V June 1, 2026, 5:00 PM ET other_material Items 1.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

Comparable filing

On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (" Live Oak "), and HB Strategies LLC (" Seller " or " FPA Investor ") entered into an agreement (the " Forward Purchase Agreement ") for an OTC Prepaid Share Forward Transaction-Optional Early Termination (the " Forward Purchase Transaction ") in connection with Live Oak’s proposed initial business combination (the " Business Combination ") with Teamshares Inc., a Delaware corporation (" Teamshares " and the surviving public company following consummation of the Business Combination, the " Combined Company "), which is the subject of the previously-disclosed Agreement and Plan of Merger entered into by Live Oak and Teamshares as of November 14, 2025 (as amended as of April 1, 2026, and as may be further amended or supplemented from time to time, the " Merger Agreement ").

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

Comparable filing

On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).

Filing page SEC filing

BBDC

Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments

Barings BDC, Inc. June 1, 2026, 4:15 PM ET other_material Items 1.01, 1.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

Comparable filing

Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

Comparable filing

A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent

Filing page SEC filing

CITR

CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights

CitroTech Inc. June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

Comparable filing

On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock

Filing page SEC filing

LTRX

Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M

LANTRONIX INC June 1, 2026, 4:15 PM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On April 28, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. (the “Underwriters”), related to a public offering (the “Offering”) of 16,744,187 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $10.75 per share.

Comparable filing

On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-197489

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.